Compugen (CGEN) Tops Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Compugen (CGEN) Tops Q1 EPS by 2c

Compugen Reports First Quarter 2022 Results

May 16, 2022 7:00 AM EDT

Triple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responsesCOM701, a unique check point inhibitor, with potential to recruit additional T cells to the TMECOM902 has the potential to be a best-in-class anti-TIGIT antibodyOn track to deliver clinical data from the cohort expansion study of COM701/nivolumab in MSS CRC in Q4 2022Enrollment continues in the Phase 1 clinical studies for COM701 and COM902Cash balance of $107 million affirms focus on capital efficiency with bold execution on Compugen's DNAM-1 axis... More